RepurpOS

Amyotrophic Lateral Sclerosis (ALS)

Disease intelligence for Amyotrophic Lateral Sclerosis: 69 alterations and 305 ranked therapeutics from curated public databases.

US DALYs1.18MWHO GHE 2021 · all ages
Global DALYs8.06MWHO GHE 2021 · worldwide
US mortality38.5K deaths/yrWHO GHE 2021
Global mortality191.2K deaths/yrWHO GHE 2021 · worldwide
NIH funding$252MFY2025 · RCDC estimate
Funding levelUnderfunded
Spontaneous remissionEssentially zero — uniformly progressive, fatal within 2-5 years median; <10% survive >10 years; spontaneous prolonged…
Best-intervention remissionRiluzole: 3-month median survival extension (modest); edaravone (Radicava): slows functional decline by 33% at 24…
Gap sizeVery large — ALS has no effective treatment; existing drugs provide modest or biomarker-based benefit; curative…
Primary barrierbiological
Full remission profile →

Disease overview

Alterations
69
Molecular (A)
20
Clinical (B–E)
47
Trial outcome measures (T)
2
Direct drugs
190
Via biomarker
118
Natural agents
0
Natural products
79
Merged ranked
305
With trial/literature evidence
25

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, Seeds, Examine.com · Pipeline phase 7 · Updated 2026-10-15

Remission & chronicity

Spontaneous remission
Essentially zero — uniformly progressive, fatal within 2-5 years median; <10% survive >10 years; spontaneous prolonged stabilisation in <1% (SOD1 heterozygous late-onset)
Best-intervention remission
Riluzole: 3-month median survival extension (modest); edaravone (Radicava): slows functional decline by 33% at 24 weeks in a specific ALS subgroup (ALSFRS-R); AMX0035 (sodium phenylbutyrate + taurursodiol): 6.5-month OS extension (CENTAUR trial — modest); tofersen (SOD1-ALS): 38% reduction in neurofilament light (biomarker); 2-year mortality benefit for SOD1-ALS
Drug-free remission
—
Relapse after remission
—
Chronicity
—
Gap size
Very large — ALS has no effective treatment; existing drugs provide modest or biomarker-based benefit; curative approaches are distant
Primary barrier
biological
Barrier detail: ALS is arguably the most therapeutically challenging neurodegenerative disease; 25+ Phase 3 trials have failed; tofersen (SOD1-targeting antisense oligonucleotide) represents the first mechanism-targeted approach and the most promising signal yet; multigenicity and sporadic forms make uniform treatment impossible

Last SoC change: 2023 — tofersen (Qalsody) FDA approved for SOD1-ALS based on neurofilament biomarker; AMX0035 (Relyvrio) approved 2022 — subsequently voluntary market withdrawal 2024 after Phase 3 PHOENIX trial failure; edaravone 2017; riluzole 1995

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0004976 · ORPHA: ORPHA:803

Alterations

69 total · Types A (molecular) through E (functional). Molecular rows are Open Targets gene–disease associations (evidence column = OT association score), not measured levels; phenotypes are HPO terms annotated directly to this disease (Monarch); type T rows are outcome measures used in completed ClinicalTrials.gov studies, not alterations of the disease.

NameTypeSubtypeDirection FrequencyEvidenceSourcesLinks
ANG
angiogenin
Molecular Gene — — OT score 0.81 Open Targets
DCTN1
dynactin subunit 1
Molecular Gene — — OT score 0.80 Open Targets
ALS2
alsin Rho guanine nucleotide exchange factor ALS2
Molecular Gene — — OT score 0.78 Open Targets
CHMP2B
charged multivesicular body protein 2B
Molecular Gene — — OT score 0.78 Open Targets
ANXA11
annexin A11
Molecular Gene — — OT score 0.78 Open Targets
ERBB4
erb-b2 receptor tyrosine kinase 4
Molecular Gene — — OT score 0.70 Open Targets
ATXN2
ataxin 2
Molecular Gene — — OT score 0.68 Open Targets
C9orf72
C9orf72-SMCR8 complex subunit
Molecular Gene — — OT score 0.66 Open Targets
CFAP410
cilia and flagella associated protein 410
Molecular Gene — — OT score 0.63 Open Targets
DAO
D-amino acid oxidase
Molecular Gene — — OT score 0.47 Open Targets
ERLIN1
ER lipid raft associated 1
Molecular Gene — — OT score 0.46 Open Targets
CCNF
cyclin F
Molecular Gene — — OT score 0.42 Open Targets
CHCHD10
coiled-coil-helix-coiled-coil-helix domain containing 10
Molecular Gene — — OT score 0.42 Open Targets
DNAJC7
DnaJ heat shock protein family (Hsp40) member C7
Molecular Gene — — OT score 0.41 Open Targets
CHRNA3
cholinergic receptor nicotinic alpha 3 subunit
Molecular Gene — — OT score 0.40 Open Targets
CCSAP
centriole, cilia and spindle associated protein
Molecular Gene — — OT score 0.36 Open Targets
DRD2
dopamine receptor D2
Molecular Gene — — OT score 0.34 Open Targets
AKAP12
A-kinase anchoring protein 12
Molecular Gene — — OT score 0.31 Open Targets
AGTPBP1
ATP/GTP binding carboxypeptidase 1
Molecular Gene — — OT score 0.30 Open Targets
ALDH1A3
aldehyde dehydrogenase 1 family member A3
Molecular Gene — — OT score 0.27 Open Targets
Abnormality on pulmonary function testing Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Amyotrophic lateral sclerosis Pathology Pathological finding — obligate HPO annotation HPO, Monarch
Anxiety Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Atypical behavior Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Babinski sign Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Cachexia Pathology Pathological finding — occasional HPO annotation HPO, Monarch
Cognitive impairment Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Depression Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Distal amyotrophy Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Drooling Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Dysarthria Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Dysphagia Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Dysphonia Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Dyspnea Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Emotional lability Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Fasciculations Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Fatigable weakness of bulbar muscles Functional Functional test — frequent HPO annotation HPO, Monarch
Fatigable weakness of respiratory muscles Functional Functional test — frequent HPO annotation HPO, Monarch
Fatigable weakness of swallowing muscles Functional Functional test — frequent HPO annotation HPO, Monarch
Fatigue Functional Functional test — frequent HPO annotation HPO, Monarch
Foot dorsiflexor weakness Functional Functional test — occasional HPO annotation HPO, Monarch
Frontotemporal dementia Pathology Pathological finding — occasional HPO annotation HPO, Monarch
Generalized muscle weakness Functional Functional test — very_frequent HPO annotation HPO, Monarch
Hoffmann sign Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Hyperreflexia Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Jaw hyperreflexia Pathology Pathological finding — occasional HPO annotation HPO, Monarch
Language impairment Pathology Pathological finding — occasional HPO annotation HPO, Monarch
Laryngospasm Pathology Pathological finding — — HPO annotation HPO, Monarch
Lower limb muscle weakness Functional Functional test — frequent HPO annotation HPO, Monarch
Motor neuron atrophy Pathology Pathological finding — very_frequent HPO annotation HPO, Monarch
Muscle spasm Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Neurodegeneration Pathology Pathological finding — very_frequent HPO annotation HPO, Monarch
Orthopnea Pathology Pathological finding — occasional HPO annotation HPO, Monarch
Pain Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Paralysis Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Progressive distal muscular atrophy Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Respiratory failure Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Skeletal muscle atrophy Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Sleep disturbance Pathology Pathological finding — occasional HPO annotation HPO, Monarch
Spastic paraparesis Pathology Pathological finding — occasional HPO annotation HPO, Monarch
Spasticity Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Steppage gait Pathology Pathological finding — occasional HPO annotation HPO, Monarch
Tongue atrophy Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Tongue fasciculations Pathology Pathological finding — occasional HPO annotation HPO, Monarch
Upper limb muscle weakness Functional Functional test — frequent HPO annotation HPO, Monarch
Weight loss Pathology Pathological finding — frequent HPO annotation HPO, Monarch
Xerostomia Pathology Pathological finding — frequent HPO annotation HPO, Monarch
ALS Functional Rating Scale Trial outcome measure Clinical scale — — Trial outcome measure ClinicalTrials.gov
Absence of adverse events Trial outcome measure Lab value — — Trial outcome measure ClinicalTrials.gov

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, and merged ranking. Only agents with registry trials or published clinical literature are shown by default.

DrugTypePhaseEvidence ScorePrice (UK / US)Trials & literatureSourcesLinks
CIPROFLOXACIN Small molecule Approved Strong 100 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
3 trials 2 Trial pubs 2 RCT
View evidence

Registry trials

  • NCT04090684 — Ciprofloxacin/Celecoxib Combination in Patients With ALS (COMPLETED) PHASE1
  • NCT05357950 — A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS (COMPLETED) PHASE2
  • NCT04165850 — Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS (COMPLETED) PHASE2

Open Targets, ChEMBL
SIROLIMUS Small molecule Approved Strong 100 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
1 trials
View evidence

Registry trials

  • NCT03359538 — Rapamycin Treatment for ALS (COMPLETED) PHASE2

Open Targets, ChEMBL
TACROLIMUS ANHYDROUS Small molecule Approved Strong 100 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
2 trials
View evidence

Registry trials

  • NCT04302870 — Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial (RECRUITING) PHASE2, PHASE3
  • NCT01884571 — Immunosuppression in Amyotrophic Lateral Sclerosis (ALS) (COMPLETED) PHASE2

Open Targets, ChEMBL
ACETAZOLAMIDE Repurposing Small molecule Approved Strong 95 UK £3–£8 / 28–56 tabs · US $8–$15 / 30 tabs — ChEMBL
AMPHETAMINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
AMSACRINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
APOMORPHINE HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
BENZOIC ACID Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
BEVACIZUMAB Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
BICALUTAMIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
CARBACHOL Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
CHLORHEXIDINE GLUCONATE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
CHLORPROMAZINE HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence
DGIdb
CLEMASTINE FUMARATE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence
DGIdb
CLOMIPRAMINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
CLOTRIMAZOLE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
1 pubs
View evidence
DGIdb
COCAINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
CYCLOSPORINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
1 trials 2 RCT
View evidence

Registry trials

  • NCT07539662 — Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) (ENROLLING_BY_INVITATION) NA

Published literature

DGIdb
DIAZEPAM Repurposing Small molecule Approved Strong 95 UK £1–£3 / 28 tabs · US $3–$8 / 30 tabs — ChEMBL
DICHLORPHENAMIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
DIETHYLSTILBESTROL Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
DOXORUBICIN HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)
No indexed hits
View evidence
DGIdb
ECONAZOLE NITRATE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
ECULIZUMAB Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
EFGARTIGIMOD ALFA Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
EPIRUBICIN Repurposing Small molecule Approved Strong 95 Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP) — ChEMBL
EPIRUBICIN HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)
No indexed hits
View evidence
DGIdb
ETHOXZOLAMIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
FENRETINIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
2 pubs
View evidence
DGIdb
FLUMAZENIL Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
FLUOXETINE HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence
DGIdb
IDARUBICIN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence
DGIdb
IDARUBICIN HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence
DGIdb
IMIPRAMINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
INDAPAMIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
INDOMETHACIN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
ISOSORBIDE DINITRATE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
MAFENIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
MAPROTILINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
MASOPROCOL Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
MECAMYLAMINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
MECAMYLAMINE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
MECAMYLAMINE HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
MEFLOQUINE HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence
DGIdb
METHAZOLAMIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
METHIXENE HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
METHOXSALEN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
METOPROLOL Repurposing Small molecule Approved Strong 95 UK £2–£4 / 28 tabs · US $4–$9 / 30 tabs — ChEMBL
MIANSERIN Repurposing Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
MITOXANTRONE Repurposing Small molecule Approved Strong 95 Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP) — DGIdb
DrugTypePhaseEvidence ScorePrice (UK / US)SourcesLinks
ABACAVIR Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
ARIMOCLOMOL Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
CEFTRIAXONE Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
CREATINE Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
CYANOCOBALAMIN Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
DEBAMESTROCEL Cell therapy Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
DEXPRAMIPEXOLE Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
DEXTROMETHORPHAN Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
DOLUTEGRAVIR Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
LAMIVUDINE Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
LEVOSIMENDAN Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
LITHIUM CARBONATE Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
MASITINIB Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
MECASERMIN Biologic Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
MINOCYCLINE Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
NABIXIMOLS Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
OLESOXIME Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
PRIDOPIDINE Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
QUINIDINE Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
RAVULIZUMAB Biologic Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
RELDESEMTIV Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
TAUROLITHOCHOLIC ACID Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
TIRASEMTIV Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
ULEFNERSEN Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
VALPROIC ACID Small molecule Phase III Moderate 80 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
ABATACEPT Biologic Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
ACETYLCARNITINE Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
ALBUMIN HUMAN Biologic Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
ALBUTEROL Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
ALDESLEUKIN Biologic Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
AMANTADINE Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
AMBROXOL Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
ANAKINRA Biologic Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
ANX-005 Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
APILIMOD MESYLATE Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
ARGX-119 Biologic Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
ARUNDIC ACID Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
ASTAXANTHIN Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
ATROPINE Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
ATSM COPPER (II) Small molecule Phase II Emerging 60 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) Open Targets
DrugTypePhaseEvidence ScorePrice (UK / US)Trials & literatureSourcesLinks
ACETAZOLAMIDE Repurposing via AGTPBP1 Small molecule Approved Strong 95 UK £3–£8 / 28–56 tabs · US $8–$15 / 30 tabs — ChEMBL
AMPHETAMINE Repurposing via AGTPBP1 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
AMSACRINE Repurposing via ATXN2 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
APOMORPHINE HYDROCHLORIDE Repurposing via ATXN2 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
BENZOIC ACID Repurposing via DAO Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
BEVACIZUMAB Repurposing via ANXA11 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
BICALUTAMIDE Repurposing via AGTPBP1 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
CARBACHOL Repurposing via AGTPBP1 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
CHLORHEXIDINE GLUCONATE Repurposing via ATXN2 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
CHLORPROMAZINE HYDROCHLORIDE Repurposing via ATXN2 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence
DGIdb
CIPROFLOXACIN Repurposing via AGTPBP1 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
3 trials 2 Trial pubs 2 RCT
View evidence

Registry trials

  • NCT04090684 — Ciprofloxacin/Celecoxib Combination in Patients With ALS (COMPLETED) PHASE1
  • NCT05357950 — A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS (COMPLETED) PHASE2
  • NCT04165850 — Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS (COMPLETED) PHASE2

ChEMBL
CLEMASTINE FUMARATE Repurposing via ATXN2 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence
DGIdb
CLOMIPRAMINE Repurposing via AGTPBP1 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
CLOTRIMAZOLE Repurposing via ATXN2 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
1 pubs
View evidence
DGIdb
COCAINE Repurposing via CHRNA3 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
CYCLOSPORINE Repurposing via ATXN2 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
1 trials 2 RCT
View evidence

Registry trials

  • NCT07539662 — Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) (ENROLLING_BY_INVITATION) NA

Published literature

DGIdb
DIAZEPAM Repurposing via AGTPBP1 Small molecule Approved Strong 95 UK £1–£3 / 28 tabs · US $3–$8 / 30 tabs — ChEMBL
DICHLORPHENAMIDE Repurposing via AGTPBP1 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
DIETHYLSTILBESTROL Repurposing via AGTPBP1 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
DOXORUBICIN HYDROCHLORIDE Repurposing via ATXN2 Small molecule Approved Strong 95 Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)
No indexed hits
View evidence
DGIdb
ECONAZOLE NITRATE Repurposing via ATXN2 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
ECULIZUMAB Repurposing via CHRNA3 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
EFGARTIGIMOD ALFA Repurposing via CHRNA3 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
EPIRUBICIN Repurposing via AGTPBP1 Small molecule Approved Strong 95 Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP) — ChEMBL
EPIRUBICIN HYDROCHLORIDE Repurposing via ATXN2 Small molecule Approved Strong 95 Hospital / IV specialty — prices per vial or dose (often hundreds–thousands USD/GBP)
No indexed hits
View evidence
DGIdb
ETHOXZOLAMIDE Repurposing via AGTPBP1 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
FENRETINIDE Repurposing via ATXN2 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
2 pubs
View evidence
DGIdb
FLUMAZENIL Repurposing via AGTPBP1 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
FLUOXETINE HYDROCHLORIDE Repurposing via ATXN2 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence
DGIdb
IDARUBICIN Repurposing via ATXN2 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence
DGIdb
IDARUBICIN HYDROCHLORIDE Repurposing via ATXN2 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US)
No indexed hits
View evidence
DGIdb
IMIPRAMINE Repurposing via AGTPBP1 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
INDAPAMIDE Repurposing via AGTPBP1 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
INDOMETHACIN Repurposing via AGTPBP1 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
ISOSORBIDE DINITRATE Repurposing via AGTPBP1 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
MAFENIDE Repurposing via AGTPBP1 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL
MAPROTILINE Repurposing via ATXN2 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
MASOPROCOL Repurposing via ATXN2 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
MECAMYLAMINE Repurposing via CHRNA3 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — DGIdb
MECAMYLAMINE Repurposing via AGTPBP1 Small molecule Approved Strong 95 Varies — check openprescribing.net (UK) or costplusdrugs.com / GoodRx (US) — ChEMBL

Natural Products

79 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked). Only agents with direct clinical evidence are shown by default.

Reference lookups: Examine.com

DrugTypePhaseEvidence ScorePrice (UK / US)Trials & literatureSourcesLinks
Creatine Natural product Amino acid Phase III Moderate 17 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 4 Cochrane 6 Meta-analysis 22 Trial pubs 9 RCT
View evidence

Registry trials

  • NCT00023075 — Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis (COMPLETED)
  • NCT02709330 — ALS Reversals - Lunasin Regimen (COMPLETED) PHASE2
  • NCT00070993 — Creatine for the Treatment of Amyotrophic Lateral Sclerosis (COMPLETED) PHASE2
  • NCT00005766 — Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis (COMPLETED) PHASE2
  • NCT00005674 — Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS] (COMPLETED) PHASE2
  • NCT01257581 — Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS) (COMPLETED) PHASE2
  • NCT00355576 — Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis (COMPLETED) PHASE2
  • NCT00069186 — Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis (UNKNOWN) PHASE3

Published literature

Examine.com
Creatine Natural product Amino acid Phase III Emerging 16 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
8 trials 4 Cochrane 6 Meta-analysis 22 Trial pubs 9 RCT
View evidence

Registry trials

  • NCT00023075 — Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis (COMPLETED)
  • NCT02709330 — ALS Reversals - Lunasin Regimen (COMPLETED) PHASE2
  • NCT00070993 — Creatine for the Treatment of Amyotrophic Lateral Sclerosis (COMPLETED) PHASE2
  • NCT00005766 — Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis (COMPLETED) PHASE2
  • NCT00005674 — Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS] (COMPLETED) PHASE2
  • NCT01257581 — Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS) (COMPLETED) PHASE2
  • NCT00355576 — Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis (COMPLETED) PHASE2
  • NCT00069186 — Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis (UNKNOWN) PHASE3

Published literature

Examine.com
Vitamin E Natural product Nutraceutical Phase III Emerging 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
3 trials 9 Trial pubs
View evidence

Registry trials

  • NCT00372879 — Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS (COMPLETED) PHASE3
  • NCT04140136 — The Efficacy and Safety of Vitamin E Mixed Tocotrienols In Patients With Amyotrophic Lateral Sclerosis (ALS) (UNKNOWN) PHASE2
  • NCT04244630 — Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial (RECRUITING) PHASE2

Published literature

Vitamin D3 Natural product Nutraceutical Preclinical Emerging 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
2 trials 1 Trial pubs
View evidence

Registry trials

  • NCT02893605 — Study of Gene Polymorphisms Involved in the Metabolism and Action of Vitamin D in Amyotrophic Lateral Sclerosis (COMPLETED)
  • NCT01823380 — Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Phenotype (COMPLETED) NA

Published literature

Vitamin B12 Natural product Nutraceutical Phase III Emerging 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
2 trials
View evidence

Registry trials

  • NCT04557410 — Open Label Study: Treatment of ALS Fatigue With PolyMVA (COMPLETED) PHASE1
  • NCT03548311 — Clinical Trial of Ultra-high Dose Methylcobalamin for ALS (COMPLETED) PHASE3

Omega-3 Fatty Acids Natural product Nutraceutical Phase II Emerging 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
3 trials
View evidence

Registry trials

  • NCT03659422 — Dietary Approach to Improving Quality of Life in Amyotrophic Lateral Sclerosis (WITHDRAWN) NA
  • NCT06280079 — Ultra-high-caloric, Fatty Diet in ALS (RECRUITING) NA
  • NCT00983983 — High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis (COMPLETED) PHASE2

Zinc Natural product Nutraceutical Phase II Emerging 10 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 trials 2 Trial pubs
View evidence

Registry trials

  • NCT01259050 — Safety Study of High Doses of Zinc in ALS Patients (COMPLETED) PHASE1, PHASE2

Published literature

Curcumin Natural product Food compound Phase II Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
2 trials 2 Trial pubs
View evidence

Registry trials

  • NCT04654689 — Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS Patients (COMPLETED) PHASE2
  • NCT04499963 — Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS) (COMPLETED) PHASE2

Resveratrol Natural product Food compound Phase II Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 trials
View evidence

Registry trials

  • NCT04654689 — Impact of the Combined Treatment of Liposomed Polyphenols With G04CB02 on the ALS Patients (COMPLETED) PHASE2

Melatonin Natural product Nutraceutical Phase II Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 trials
View evidence

Registry trials

  • NCT06429059 — ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments (COMPLETED) PHASE2

Coenzyme Q10 Natural product Nutraceutical Phase II Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
2 trials 1 Meta-analysis 3 RCT
View evidence

Registry trials

  • NCT00243932 — Clinical Trial of High Dose CoQ10 in ALS (COMPLETED) PHASE2
  • NCT06429059 — ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments (COMPLETED) PHASE2

Published literature

Alpha-Lipoic Acid Natural product Nutraceutical Phase I Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
2 trials
View evidence

Registry trials

  • NCT04518540 — Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral Sclerosis (UNKNOWN) NA
  • NCT04557410 — Open Label Study: Treatment of ALS Fatigue With PolyMVA (COMPLETED) PHASE1

Ashwagandha Natural product Ayurvedic Phase II Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
2 trials
View evidence

Registry trials

  • NCT06429059 — ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments (COMPLETED) PHASE2
  • NCT05031351 — NF-κB Inhibition in Amyotrophic Lateral Sclerosis (UNKNOWN) PHASE2

Selenium Natural product Nutraceutical Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
No indexed hits
View evidence
Ginseng Natural product Botanical Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
16 pubs
View evidence
Probiotics Natural product Probiotic Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
2 trials
View evidence

Registry trials

  • NCT03324399 — A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS (COMPLETED) NA
  • NCT06051123 — Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients (RECRUITING) NA

Astragalus Natural product TCM herb Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
1 Cochrane
View evidence
L-Arginine Natural product Amino acid Preclinical Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
2 Trial pubs
View evidence
Niacin Natural product Nutraceutical Phase II Emerging 7 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
5 trials
View evidence

Registry trials

  • NCT03489200 — EH301 for the Treatment of ALS (COMPLETED) NA
  • NCT07414212 — Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS) (RECRUITING) PHASE1, PHASE2
  • NCT05095571 — A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study (RECRUITING) NA
  • NCT04562831 — The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS. (ACTIVE_NOT_RECRUITING) NA
  • NCT04244630 — Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial (RECRUITING) PHASE2

Vitamin B12: Methylcobalamin Natural product Nutraceutical Phase III Emerging 6 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US)
2 trials
View evidence

Registry trials

  • NCT04557410 — Open Label Study: Treatment of ALS Fatigue With PolyMVA (COMPLETED) PHASE1
  • NCT03548311 — Clinical Trial of Ultra-high Dose Methylcobalamin for ALS (COMPLETED) PHASE3

Insulin-Like Growth Factor (Igf-1) Natural product Nutraceutical Phase I Emerging 3 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Polyunsaturated Fatty Acids (PUFAs) Natural product Nutraceutical Phase I Emerging 3 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Ginkgo Biloba Natural product Botanical Preclinical Emerging 2 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Cannabidiol Natural product Food compound Preclinical Emerging 2 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Cannabinoids Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Estradiol (E(2)) Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Cannabis Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Progesterone Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Bee Venom Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Glycoaminoglycans Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Polyphenols Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Testosterone Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Antioxidant Formulas Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
EGCG (Epigallocatechin Gallate) Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Stilbenes Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Fruit: All Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Vegetables: All Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Glutathione Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Anthocyanins Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Genistein Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Rosmarinic Acid Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Coconut Oil Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Hesperidin Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Red Wine Extract Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Flavonoids Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Capsaicin Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Peony Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Salvia Miltiorrhiza Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
B-Complex Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Traditional Chinese Medicine: Jwsjz Decoction Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Copper Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Superoxide Dismutase Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Whey Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Catechin Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Honokiol Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Palmitoylethanolamide Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Galactooligosaccharides Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Arginine-Alpha-Ketoglutarate (Aakg) Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
GABA (Gamma-Aminobutyric Acid) Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Medium Chain Triglycerides Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Strawberry Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Glycyrrhiza Uralensis Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Baicalein Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Amino Acids: Branched Chain Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Caprylic Acid Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Fisetin Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Phytoestrogens Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Riboflavin (Vitamin B-2) Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Carnosic Acid Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Pterostilbene Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Oxaloacetate Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Sophora Flavescens Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Burdock Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Pyruvate Natural product Food compound Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Rosemaric Acid Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Rosemary Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Scolopendra Subspinipes Mutilans Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
Wen Pi Tang Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —
5-HTP (5-Hydroxytryptophan) Natural product Nutraceutical Preclinical Emerging 0 Varies — openprescribing.net (UK) / costplusdrugs.com or GoodRx (US) —

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Generated by OSMF Disease Intelligence Pipeline · Schema 1.1.0